Francis, Jasmine H
Mayo Clinic
Ophthalmic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Citations 2
Long-term outcomes with single-agent BRAF inhibitor therapy in Erdheim-Chester disease
Goyal, Gaurav , Bossert, Dana, Sigler, Allison , Rotemberg, Veronica , Francis, Jasmine H. , Rampal, Raajit K. , Diamond, Eli L. , Reiner, Anne S , Francis, Jasmine H , Diamond, Eli L , Goyal, Guarav , Reiner, Anne S. , Lacouture, Mario E. , Go, Ronald S.
Blood | March 7, 2025 | Volume: 145 | Issue: 18 | Pages: 2100-2103
Abstract Among 64 patients with Erdheim-Chester disease treated with a BRAF inhibitor (median follow-up 4 years), we found high response rates (85%) but frequent discontinuations (61%), primarily because of adverse events. Additionally, patients experienced poor health-related quality of life and high symptom burden.
Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference
Pe’er, Jacob, Cardoso, Fátima , Carvalho, Carlos , Coupland, Sarah E. , Desjardins, Laurence , Francis, Jasmine H. , Gombos, Dan S. , Kaliki, Swathi , Maeurer, Markus , Pulido, José S. , Ryll, Bettina , Zhao, Junyang , Parreira, A , O’Brien, Joan M. , Cardoso, Fatima , Smith, Justine R. , Neto, Rubens Belfort , Carvajal, Richard D. , Gallie, Brenda L. , Grossniklaus, Hans E. , Heegaard, Steffen , Jager, Martine Johanna , Ksander, Bruce R. , Moreno, Eduardo , Singh, Arun D. , Wilson, David John , Francis, Jasmine H
Translational Vision Science & Technology | January 10, 2019 | Volume: 8 | Issue: 1 | Pages: 9